http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5444639-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2de3beee83d9c19278da409b72c777a8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-937
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C401-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08L5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-937
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-215
filingDate 1977-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c30f1dd522a09387a886b20c2c96edd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59b72f1da74dc80480bf5c440b9dc994
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_156db00e2d809bd00983d9dfed3f70f8
publicationDate 1979-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S5444639-A
titleOfInvention Prostaglandin analog and its preparation
abstract NEW MATERIAL:Prostaglandin analogs of formulaI[Y is trans-vinylene, ethylene; R 1 is H alkyl; R 2 is H, methyl, ethyl; R 3 is single bond, alkylene; R 4 is H, alkyl, cycloakyl, phenyl, phenoxy; is α-conformation, β-conformation, that is, S- and R-conformations or their mixture]or their clathrate with cyclodextrin or nontoxic salts when R 1 is H. n EXAMPLE: (13E)-(9α, 11α, 15S)-6-oxo-9-hydroxy-11,15-bis (tetrahydropyran-2-ylocy)- prosto-13-enioc methyl ester. n USE: Medicines for hypertension, disturbance of peripheral circulation, cardiac infarction, peptic ulcer and so on. n PREPARATION: OR 5 group of the compound of formulaII (R 5 is tetrapyrane-2-yl) is hydrolyzed to OH group, thus forming the objective compound of formulaI. n COPYRIGHT: (C)1979,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H025745-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6130554-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S55141465-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S60161967-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S60181068-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H01502750-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8503935-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4797506-A
priorityDate 1977-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54377792
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393705
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559542
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6325
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394858
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID236744897

Total number of triples: 45.